Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial-Reference-Cited by-同舟云学术

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

Published:2021-08-20 Issue:11 Volume:35 Page:2225-2238
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Cowan R.A.¹^ORCID,Scarisbrick J.J.²,Zinzani P.L.³⁴,Nicolay J.P.⁵,Sokol L.⁶,Pinter‐Brown L.⁷,Quaglino P.⁸^ORCID,Iversen L.⁹,Dummer R.¹⁰^ORCID,Musiek A.¹¹,Foss F.¹²,Ito T.¹³,Rosen J‐P.¹⁴,Medley M.C.¹⁴

Affiliation:

1. Christie Hospital Foundation NHS Trust University of Manchester Manchester UK

2. University Hospital Birmingham Birmingham UK

3. IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italia

4. Istituto di Ematologia ‘Seràgnoli’ Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi Bologna Italia

5. University Medical Centre Mannheim Mannheim Germany

6. Moffitt Cancer Center Tampa FL USA

7. Chao Family Comprehensive Cancer Center University of California‐Irvine Orange CA USA

8. University of Turin Turin Italy

9. Department of Dermatology Aarhus University Hospital Aarhus Denmark

10. Universitäts Spital Zürich Zürich Switzerland

11. Division of Dermatology Washington University in Saint Louis St. Louis Missouri USA

12. Hematology and Stem Cell Transplantation Yale School of Medicine New Haven Connecticut USA

13. Kyowa Kirin Pharmaceutical Development, Inc. Princeton NJ USA

14. Kyowa Kirin International Buckinghamshire UK

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.17523

Reference20 articles.

1. Incidence of Cutaneous T-Cell Lymphoma in the United States, 1973-2002

2. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

3. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas

4. Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

5. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

2. Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome;Dermatology Reports;2024-05-07

3. Advances in the pharmacological management of cutaneous T-cell lymphoma;Expert Opinion on Pharmacotherapy;2024-05-02

4. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments;Antibodies;2024-04-22

5. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides;Nature Communications;2024-01-25